Most patients with resected non-small cell lung cancer (NSCLC) preferred a collaborative role in decision-making about adjuvant chemotherapy, a study published in the journal Lung Cancer has shown.1
Because patients with cancer have differing preferences for involvement in decision-making, researchers sought to determine the preferred and perceived involvement in decision-making among patients considering adjuvant chemotherapy following resection of early NSCLC.
For the study, researchers enrolled 98 patients to complete a self-administered questionnaire assessing preferred and perceived decision-making role at baseline and 6 months. Of those, 75 completed the 6-month questionnaire.
Results showed that the preferred role in decision-making at baseline was active in 27%, collaborative in 47%, and passive in 27% of the 98 patients; however, perceived decision-making roles only matched the preferred role in 79% of patients.
Researchers also found that preferring an active role was associated with university education (OR, 2.9; P=.02), opting to forego adjuvant chemotherapy (OR, 5.0; P<.01), and worse health-related quality of life during adjuvant chemotherapy.
The study also demonstrated that patients who preferred an active decision-making role felt that a larger survival benefit was necessary to make adjuvant chemotherapy worthwhile compared with those who preferred a passive role. Specifically, physical well-being (OR, 4.4; P=.05), overall well-being (OR, 5.5; P=.02), sleep (OR, 8.4; P<.01), and shortness of breath (OR, 7.6; P=.01) were linked with preferring a more active role.
“Clinicians should elicit and consider patients’ preferences for involvement in decision-making when discussing [adjuvant chemotherapy] for NSCLC,” the authors conclude.
1. Moth E, McLachlan SA, Veillard AS, et al. Patients’ preferred and perceived roles in making decisions about adjuvant chemotherapy for non-small-cell lung cancer [published online ahead of print February 20, 2016]. Lung Cancer. doi:10.1016/j.lungcan.2016.02.009.